Return to search

Die Effekte der exogenen, equinen Parathormon-Applikation (ePTH 1-37) auf den Kalzium- und Knochenstoffwechsel beim Pferd.

In recent years, the intermittent, exogenous application of parathyroid hormone fragment has been established as a therapeutic agent for human osteoporosis. The present placebo-controlled trial evaluated the effects of intermittent, exogenous application of equine parathyroid hormone fragment (ePTH 1-37) on calcium homeostasis and bone metabolism in healthy horses. The dose-response relationship and an appropriate daily treatment scheme with ePTH (1-37) were assessed with 0.5, 1, 5, 10, and 40 µg ePTH (1-37)/kg BW to provide a basis for long-term ePTH (1-37) application. The dose selection of 0.5 µg ePTH (1-37)/kg KM for long-term application resulted from a short, temporary increase in the ionized blood calcium level after ePTH (1-37) injection and an unimpaired fractional calcium and phosphorus excretion. Higher dosages caused adverse events such as persisting hypercalcemia and general condition disturbance after 2 or 3 days of treatment. In a subsequent attempt, 6 horses each received either ePTH (1-37) or placebo for 120 days by daily subcutaneous injections. The diurnal response of calcium in blood reflected the responsiveness of the target cells to exogenous application of ePTH (1-37). During the observation period, cancellous bone mineral density increased significantly, but showed no differences between ePTH treatment and placebo. After long-term application, parathyroid response and endogenous intact parathyroid hormone release were investigated using Na2EDTA-induced hypocalcemia. Previously ePTH-treated horses showed moderately reduced levels of endogenous intact PTH when compared to those results obtained in the placebo group. Concomitant, ePTH-treated horses appeared to have a more rapid and improverd recovery of calcium homeostasis. In general, the long-term intermittent application of 0.5 µg ePTH (1-37)/kg BW seemed to have no negative effects in healthy horses. The potential area of ePTH application in horses could be osteoporotic stages, for instance, as observed in podotrochlosis and glucocorticoid-induced bone loss.

Identiferoai:union.ndltd.org:DRESDEN/oai:qucosa.de:bsz:15-qucosa-65480
Date01 March 2011
CreatorsWeisrock, Katharina Uta
ContributorsUniversität Leipzig, Veterinärmedizinische Fakultät, Prof. Dr. Arwid Daugschies, Prof. Dr. Manfred Coenen
PublisherUniversitätsbibliothek Leipzig
Source SetsHochschulschriftenserver (HSSS) der SLUB Dresden
Languagedeu
Detected LanguageEnglish
Typedoc-type:doctoralThesis
Formatapplication/pdf

Page generated in 0.0017 seconds